72.11.Z - Research and experimental development on biotechnology
10.89.Z - Manufacture of other food products not elsewhere classified
20.42.Z - Manufacture of perfumes and toilet preparations
21.10.Z - Manufacture of basic pharmaceutical substances
21.20.Z - Manufacture of medicines and other pharmaceutical products
71.20 - Technical testing and analysis
72.19.Z - Other research and experimental development on natural sciences and engineering
74.10.Z - Specialised design activities
74.90.Z - Other professional, scientific and technical activities not elsewhere classified
85.60.Z - Educational support activities
2019 | 2020 | 2021 | ||
---|---|---|---|---|
K PLN | K PLN | K PLN | % | |
Assets | 865,5 | 279,4 | 290,9 | 4,1 |
Gross profit (loss) | 22,3 | -121,3 | -163,4 | -34,6 |
EBITDA | 28,8 | -59 | -3,2 | 94,5 |
Net profit (loss) | 19,5 | -121,3 | -163,4 | -34,6 |
Cash | 773 | 14,7 | 41,3 | 181,3 |
Net income from sale | 82,6 | 39 | 0,2 | -99,5 |
Liabilities and provisions for liabilities | 613,8 | 135,6 | 97,9 | -27,8 |
Short time liabilities | 62,6 | 0,8 | 0,5 | -33,1 |
Working assets | 813,1 | 40,8 | 49,9 | 22,2 |
Equity capital | 251,7 | 143,8 | 193 | 34,1 |
Operating profit (EBIT) | 22,3 | -117,9 | -163,4 | -38,5 |
Depreciation | 6,5 | 58,9 | 160,1 | 171,8 |
% | % | % | p.p. | |
Profitability of capital | 7,8 | -84,4 | -84,7 | -0,3 |
Equity capital to total assets | 29,1 | 51,5 | 66,3 | 14,8 |
Gross profit margin | 27 | -310,9 | -83 017,7 | -82 706,8 |
EBITDA Margin | 34,9 | -151,3 | -1650,7 | -1499,4 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 277 | 7 | 937 | 930 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane